Basal Cell Carcinoma

LEXINGTON, Mass., Oct. 29, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a combination of existing and new investors for the purchase of 2,398,414 shares of its common stock in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Curis also agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to an aggregate of 2,398,414 shares of common stock. The unregistered warrants to be issued in the concurrent private placement will have an exercise price of $4.92 per share of common stock, will be exercisable immediately and will expire five years following the issuance date. The combined purchase price for one share of common stock and the associated unregistered warrant is $5.045. Gross proceeds to Curis from the offering are expected to be approximately $12.1 million, before deducting the placement agents' fees and other offering expenses payable by Curis. Curis intends to use the net proceeds from the offering on research, development, working capital, and other general corporate purposes. The registered direct offering and concurrent private placement are each expected to close on or about October 30, 2024, subject to the satisfaction of customary closing conditions. Truist Securities and Laidlaw & Company (U.K.) Ltd. are acting as placement agents for the registered direct offering and the concurrent private placement. The shares of common stock offered in the registered direct offering (but excluding the unregistered warrants to be issued in the concurrent private placement and shares of common stock underlying the unregistered warrants) are being offered by Curis pursuant to a shelf registration statement on Form S-3 (File No. 333-276950) that was filed with the U.S. Securities and Exchange Commission ("SEC") on February 8, 2024 and declared effective by the SEC on April 12, 2024. A prospectus supplement relating to and describing the terms of the registered direct offering will be filed with the SEC and will be available on the SEC's website at . The registered direct offering is being made only by means of a prospectus and related prospectus supplement. When available, electronic copies of the prospectus supplement and the accompanying prospectus may also be obtained from Truist Securities, Inc., Attention: Prospectus Department, 3333 Peachtree Road NE, 9th floor, Atlanta, Georgia 30326, by telephone at (800) 685-4786, or by email at [email protected]; and Laidlaw & Company (U.K.) Ltd., Attention: [email protected]. The unregistered warrants are being offered in the concurrent private placement pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), provided in Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying such unregistered warrants, have not been registered under the Securities Act or applicable state securities laws. Curis has agreed to file a resale registration statement with the SEC covering the resale of the shares of common stock underlying the unregistered warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Curis, Inc. Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with either a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as a frontline combination therapy with azacitidine and venetoclax in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, any statements with respect to Curis's registered direct offering and concurrent private placement, anticipated use of proceeds, prospects for Curis and the expected closing of the registered direct offering and the concurrent private placement. Forward-looking statements may contain the words "believes," "expects," "anticipates," "plans," "intends," "seeks," "estimates," "assumes," "predicts," "projects," "targets," "will," "may," "would," "could," "should," "continue," "potential," "focus," "strategy," "mission" or similar expressions. Actual results may differ materially from those indicated by such forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to market and other conditions, the satisfaction of customary closing conditions related to the registered direct offering and the concurrent private placement and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that Curis will be able to complete the registered direct offering and the concurrent private placement on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements. Additional risks and uncertainties relating to the registered direct offering, Curis and its business can be found under the caption "Risk Factors" included in Curis's Annual Report on Form 10-K for the year ended December 31, 2023, Curis's prospectus supplement to be filed with the SEC, and in other filings that Curis periodically makes with the SEC. In addition, any forward-looking statements included in this press release represent the view of Curis only as of today and should not be relied upon as representing Curis's views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by law. SOURCE Curis, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Data from a wide range of the Sun Pharma dermatology portfolio, including data on alopecia areata, psoriasis, acne and actinic keratosis products, will be highlighted during the meeting. MUMBAI, India and PRINCETON, N.J., Oct. 25, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or affiliated companies, "Sun Pharma") today announced it will present more than a dozen posters at the 44th Annual Fall Clinical Dermatology Conference, being held October 24-27, 2024, in Las Vegas, Nevada. The presentations will include data from across the Sun Pharma dermatology portfolio, including study results for LEQSELVI™ (deuruxolitinib), WINLEVI® (clascoterone), ILUMYA® (tildrakizumab-asmn), ODOMZO® (sonidegib) and LEVULAN® KERASTICK® (aminolevulinic acid HCl) + BLU-U® (blue light photodynamic therapy). "As an organization dedicated to supporting the dermatology community, the Fall Clinical Dermatology Conference offers a vitally important forum to present new data and highlight how Sun's innovative dermatology portfolio can support those living with alopecia areata, psoriasis, acne and other skin-related diseases," said Marek Honczarenko, MD, PhD, Senior Vice President and Head of Global Development at Sun Pharma. "We look forward to sharing data from across our portfolio with the dermatology research community and our esteemed industry colleagues." Six abstracts, accepted for poster presentations, will highlight clinical efficacy and safety data of LEQSELVI™ (deuruxolitinib). Approved earlier this year by the U.S. Food and Drug Administration for the treatment of adults with severe alopecia areata, LEQSELVI™ is an oral JAK inhibitor that interrupts the pathways thought to contribute to hair loss in severe AA and delivered statistically significant efficacy at 24 weeks across two Phase 3 clinical trials. LEQSELVI™ data being presented at Fall Clinical showcase pooled long-term results for ongoing clinically meaningful improvements in scalp hair regrowth in adults with alopecia areata. Additionally, two posters will present patient and clinician preferences for the treatment of alopecia areata. The WINLEVI® poster presentations will include new data showing significant reductions in casual facial sebum levels from baseline, stability in the presence of other commonly prescribed acne medications, and efficacy and safety from a pilot study in patients with skin of color. The conference will also feature data from three additional WINLEVI® studies. Sun Pharma will present the following posters at the 2024 Fall Clinical Dermatology Conference: LEQSELVI™ Presentations: Deuruxolitinib results in ongoing clinically meaningful improvements in scalp hair regrowth in adults with alopecia areata: Pooled long-term efficacy and safety data from the open-label extension studies Patient Preferences for the Treatment of Alopecia Areata A Discrete Choice Experiment to Assess Clinician Preferences for the Treatment of Alopecia Optimization of deuruxolitinib dosing in adult patients with alopecia area: Results from a randomized, parallel-group, multicenter Phase 2 trial Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials Improvement in anxiety and depression in adult patients with severe alopecia areata treated with deuruxolitinib: Pooled data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials WINLEVI® Presentations: Clinical evaluation of the sebum reduction induced by clascoterone cream 1%: Week 12 interim analysis Assessment of clascoterone cream 1% levels when layered with other topical acne medications Efficacy and safety of clascoterone cream 1% in patients with acne with skin of color: 16-week interim analysis The efficacy and safety of clascoterone cream 1% for the treatment of acne vulgaris are not dependent on patient age and sex: Results of a post hoc analysis Improvement in skin moisturization and lack of barrier damage with clascoterone cream 1% treatment: Results of a randomized, single-blind, split-face study in acne-prone individuals Comparison of the efficacy of clascoterone vs trifarotene and tazarotene for the treatment of acne vulgaris at Week 12: A systematic review and meta-analysis ILUMYA® Presentation: A systematic literature review and meta-analysis of the real-world effectiveness, quality of life, and safety of tildrakizumab for moderate-to-severe plaque psoriasis ODOMZO® Presentation: Lower rate of discontinuation of sonidegib compared to vismodegib in a real-world analysis of patients with basal cell carcinoma LEVULAN® KERASTICK® + BLU-U® Presentation: Evaluating the safety and efficacy of aminolevulinic acid 20% topical solution activated by blue light in the treatment of facial cutaneous squamous cell carcinoma in situ About Sun Pharmaceutical Industries Limited. (CIN – L24230GJ1993PLC019050) Sun Pharma is the world's leading specialty generics company with a presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. For further information, please visit and follow us on LinkedIn & X (Formerly Twitter). Disclaimer: Statements in this "document" describing Sun Pharma's objectives, projections, estimates, expectations, plans or predictions, industry conditions, or events may be "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. Sun Pharma does not undertake any obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof. SOURCE Sun Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

American Cancer Society and American Cancer Society Cancer Action Network volunteers Danyelle Musselman and Flecia R. Brown discuss how getting involved in research and advocacy can reduce cancer disparities for future generations ATLANTA, Oct. 24, 2024 /PRNewswire/ -- The American Cancer Society's recently released 2024 Breast Cancer Facts and Figures report finds breast cancer mortality rates overall have dropped by 44% since 1989, averting approximately 517,900 breast cancer deaths. However, Black women are less likely to survive their breast cancer regardless of stage at diagnosis. In addition, cancer research and other discoveries have contributed to a 33 percent age adjusted reduction in cancer mortality rates since rates peaked in 1991. But despite these significant strides, Black women continue to have the highest death rate and the shortest survival of any racial or ethnic group in the U.S. for most cancers. To address these issues, many in the Black community have partnered with organizations and healthcare systems to use their voices to educate about risk factors, support those diagnosed, advocate for public policies and engage in research to improve cancer disparities. To talk about how Black women can use their voices to address this ongoing issue, American Cancer Society and American Cancer Society Cancer Action Network volunteers Danyelle Musselman and Flecia R. Brown discuss the importance of getting involved in population research and advocating for policies that improve prevention and treatment. Danyelle Musselman is a former national sports anchor and is married to current USC Head Men's Basketball Coach Eric Musselman. They share three children: Michael, Matthew and Mariah. Musselman has worked with ACS and ACS CAN for the past 8 years through fundraising and advocacy. She got involved after her mom's breast cancer diagnosis following the loss of her grandmother to ovarian cancer and her grandfather to lung cancer. 1 – Knowing the history of mistreatment and abuse of Black communities when it comes to health and research, why do you think it's important to get involved in cancer research? Most of us in the Black community know the terrible history our ancestors were subjected to in the name of advancing medical knowledge, but we can't let that keep us from partnering with researchers who need our community to advance research the right way. For example, I got involved in the American Cancer Society's VOICES of Black Women study when I learned that the study was being led by two women of color along with an advisory board of Black women who are cross-disciplinary experts in Black women's health. That along with the American Cancer Society's 70-year history of funding and conducting some of the world's largest population cohort studies that have contributed to major discoveries like the linkage of cigarette smoke to lung cancer convinced me that I was in good hands. 2 – What is VOICES of Black Women and what is your pitch to Black women when encouraging them to enroll in the study? Just that if not us, who? If we don't actively participate in improving our own outcomes, how do we get it done? We know we're directly impacted by family history or access to screening and treatment due to insurance or income, but we have to dig deeper and really uncover the behavioral and environmental causes of the disparities we're seeing. We can't do that if we can't gather the data. This study explores topics like how racism, discrimination, social support, and generational wealth impact cancer risk and health seeking behaviors. This gives us the data to reinforce the importance of addressing these issues from a health perspective. In my view, it's about legacy, how can I play a small part in improving outcomes for generations to come. 3 – How are you helping the American Cancer Society broaden its reach and get to the study's goal of 100,000 Black women? I'm an official trained VOICES ambassador which means I've raised my hand along with over 100 other Black women nationwide to make sure other women we know are aware of the study and its importance. The research team is being very intentional about making sure this study is conducted as a partnership between the organization and Black women. Through ambassadors, we are reaching Black women wherever they are – local organizations, churches, sororities, etc. The other key point we want them to know is enrolling in the study means they are very much part of a movement to really see advancements in our own health. The American Cancer Society is committed to communicating with participants on a consistent basis regarding findings and results. 4 – Who is eligible to participate and how can a Black woman enroll? It's key that Black women between the ages of 25 and 55 who have no cancer history except basal or squamous skin cancer are part of the study so researchers can follow their journey. You also must be in one of our 20 enrollment states or DC. They can go to voices.cancer.org to learn more. I urge the women reading this to let all the women in your network know that we must participate to change outcomes. Flecia R. Brown has been a volunteer for ACS and ACS CAN for over 15 years. Flecia is an 18-year survivor of stage III triple-negative breast cancer. Cancer has touched Flecia's life in many ways. In addition to her own cancer journey, she has lost many family members, including her father, four uncles and her grandmother, to the disease. This has ignited Flecia's commitment to advocating for issues related to cancer prevention and early detection. 5 – Why is advocacy important to reducing cancer disparities in the Black community?? The doctor's office isn't the only place where decisions are being made about cancer. Lawmakers and policymakers in local, state and federal government also make many important decisions that have an impact on the fight against cancer. Advocacy can push lawmakers and policymakers to pass laws and fund programs that help reduce the unequal cancer burden in the Black community like those that improve access to cancer screening and treatment services. 6 – What do you do as an advocacy volunteer for ACS CAN? When I was diagnosed with breast cancer in 2005, I was self-employed at the time and knew I wouldn't be able to afford my care. Thanks to the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) -- which provides breast and cervical screenings and treatment referral services to those who are uninsured, underinsured or have limited-income -- I was able to complete my treatments without financial burden. I advocate for funding of the NBCCEDP and tell my story because no person should have to go through cancer with financial worries. As lead ACS CAN volunteer for Georgia's 14th Congressional District. I help mobilize ACS CAN volunteers in the district in support of grassroots campaigns on issues that impact the fight against cancer. I work with them and ACS CAN staff to build relationships with elected officials in our community and advocate for laws that help reduce the cancer burden. I am also a member of ACS CAN's Black Volunteer Caucus (BVC). The BVC works to decrease death and suffering from cancer, specifically in the Black community, and ensure no one is disadvantaged in the fight against the disease. We engage in meaningful advocacy and policy work nationally and locally such as hosting fireside chats to bring together researchers, physicians, legislators and allies to discuss the unique cancer disparities Black people face and policy solutions to address them. 7 – How can other Black women use their voice in communities to advocate for laws that help reduce the cancer burden in their communities? We can't end cancer as we know it for everyone if we don't increase access to quality, affordable health care. There are several ways Black women can help. They can become a volunteer and work with advocacy organizations like ACS CAN to advocate for policy changes at all levels of government. Because cancer is an election issue, they can also make their voices heard by making a plan to vote and taking the time to register to vote or check their voter registration. To learn more and enroll in the American Cancer Society's VOICES of Black Women study, visit voices.cancer.org. To learn more about ACS CAN's advocacy work in your community and become a volunteer, visit fightcancer.org/bvc. About The American Cancer Society The American Cancer Society is a leading cancer-fighting organization with a vision to end cancer as we know it, for everyone. For more than 110 years, we have been improving the lives of people with cancer and their families as the only organization combating cancer through advocacy, research, and patient support. We are committed to ensuring everyone has an opportunity to prevent, detect, treat, and survive cancer. To learn more, visit cancer.org or call our 24/7 helpline at 1-800-227-2345. Connect with us on Facebook, X, and Instagram. About ACS CAN The American Cancer Society Cancer Action Network (ACS CAN) advocates for evidence-based public policies to reduce the cancer burden for everyone. We engage our volunteers across the country to make their voices heard by policymakers at every level of government. We believe everyone should have a fair and just opportunity to prevent, detect, treat, and survive cancer. Since 2001, as the American Cancer Society's nonprofit, nonpartisan advocacy affiliate, ACS CAN has successfully advocated for billions of dollars in cancer research funding, expanded access to quality affordable health care, and advanced proven tobacco control measures. We stand with our volunteers, working to make cancer a top priority for policymakers in cities, states and our nation's capital. Join the fight by visiting .  SOURCE American Cancer Society WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED